ATP6AP2 knockdown in cardiomyocyte deteriorates heart function via compromising autophagic flux and NLRP3

Lei Li1,2, Ya-Juan Cui3, Yu Liu1

  • 1Department of Cardiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, 250012, Jinan, China.

Cell Death Discovery
|April 5, 2022
PubMed

Insights

Upregulation of (Pro)renin receptor (ATP6AP2) is a heart

Area of Science:

  • Cardiovascular Biology
  • Cellular Stress Response
  • Molecular Mechanisms of Disease

Background:

  • Autophagy removes cellular damage, and can protect against inflammatory diseases like NLRP3 inflammasome activation.
  • (Pro)renin receptor (ATP6AP2) is essential for autophagy, but its role in pathological conditions like heart failure is unclear.
  • Pressure overload stress impacts cardiac function, autophagic flux, and inflammatory pathways.

Purpose of the Study:

  • To investigate the role of ATP6AP2 in pressure overload-induced heart failure.
  • To explore the interplay between ATP6AP2, autophagic flux, and NLRP3 inflammasome activation.
  • To determine the therapeutic potential of modulating ATP6AP2 or NLRP3 in heart failure.

Main Methods:

  • Utilized a mouse model of pressure overload (TAC) with ATP6AP2 knockdown and overexpression.
  • Assessed cardiac function, fibrosis, hypertrophy, and autophagic flux markers (e.g., SQSTM1/P62).
  • Investigated cellular responses in neonatal rat ventricular myocytes (NRVMs) and the impact of NLRP3 inhibition.

Main Results:

  • ATP6AP2 expression increased following pressure overload, correlating with autophagic flux blockage and NLRP3 activation.
  • ATP6AP2 knockdown worsened heart failure, fibrosis, and NLRP3 activation, while increasing ROS production.
  • ATP6AP2 overexpression improved autophagic flux but did not prevent TAC-induced cardiac dysfunction; NLRP3 blockade partially rescued cardiac function.

Conclusions:

  • ATP6AP2 upregulation is a compensatory response to pressure overload stress.
  • Inadequate compensation of ATP6AP2 compromises autophagic flux, leading to mitochondrial dysfunction, ROS production, and NLRP3 activation, accelerating heart failure.
  • Targeting ATP6AP2 or NLRP3 may offer therapeutic strategies for heart failure.